Abstracts tagged "Familial Mediterranean fever"

Abstract Number: 046 • 2023 Pediatric Rheumatology Symposium
Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors
Yoel Levinsky¹, rotem tal², Liora Harel³ and Gil Amarilyo⁴, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ³Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ⁴Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: IL-1 inhibitor are approved for familial Mediterranean fever (FMF) patients who are resistant to colchicine. However, it is imperative to continue concomitant treatment with…
Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Katy shehadeh¹, Yoel Levinsky², rotem tal³, Neta Hana Aviran³, Yonatan Butbul Aviel⁴, Irit Tirosh⁵, Shelly Kagan⁶, Tarek Zoabi³, Shiri Spielman⁷, Adi Miller-Barmak⁴, Rotem Semo Oz⁸, Liora Harel⁹, Gabriel Chodick¹⁰ and Gil Amarilyo⁶, ¹Tel Aviv University, Tel Aviv, Israel, ²Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Rambam Medical center, Haifa, Israel, ⁵Sheba Medical Center, Savyon, Israel, ⁶Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Sheba Tel-HaShomer Medical Center, Givataim, Israel, ⁸Sheba medical center, Herzelyia, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Maccabitech institute for research and innovation, Maccabi healthcare services, Tel Aviv, Israel
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…
Abstract Number: 0192 • ACR Convergence 2021
Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment in Patients with Familial Mediterranean Fever – Interim Analysis of the RELIANCE Registry
Jorg Henes¹, Norbert Blank², Tilmann Kallinich³, Frank Dressler⁴, Gerd Horneff⁵, Ivan Foeldvari⁶, Markus Hufnagel⁷, Birgit Kortus-Goetze⁸, Frank Weller-Heinemann⁹, Florian Meier¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹University Hospital Tuebingen, Tuebingen, Germany, ²Rheumatology, University Hospital Heidelberg, Eppelheim, Germany, ³Charité University Medicine, Nuremberg, Germany, ⁴Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Hamburger Zentrum fuer Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁷Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁸Division of Nephrology, University of Marburg, Marburg, Germany, ⁹Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ¹⁰1 Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany 2 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt am Main, Germany, Frankfurt a.M., Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²Pediatric Rheumatology and Autoinflammatory Reference Center, University Children's Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is characterized by severe systemic and organ inflammation. Successful treatment with rapid remission of symptoms and normalization of laboratory parameters…
Abstract Number: 087 • 2020 Pediatric Rheumatology Symposium
Standardizing Care and Fostering Systemic Autoinflammatory Disease (SAID) Research Through the CARRA Autoinflammatory Disease Network
Grant Schulert¹, Julie Cherian ², Theresa Wampler Muskardin ³, Marinka Twilt ⁴, Shoghik Akoghlanian ⁵, Gil Amarilyo ⁶, Dilan Dissanayake ⁷, Karen Durrant ⁸, Polly Ferguson ⁹, Maria Gutierrez ¹⁰, Liora Harel ¹¹, Jonathan Hausmann ¹², Merav Heshin Bekenstein ¹³, Ronald Laxer ⁷, Aleksander Lenert ⁹, Suzanne Li ¹⁴, Greg Licameli ¹⁵, Geraldina Lionetti ¹⁶, Ian Michelow ¹⁷, Lakshmi Moorthy ¹⁸, Evan Propst ¹⁹, Vivian Saper ²⁰, Hemalatha Srinivasalu ²¹, Yuriy Stepanovskiy ²², Akaluck Thatayatikom ²³, Lori Tucker ²⁴, Peter Wright ²⁵, Cagri Yildirim-Toruner ⁵, Fatma Dedeoglu ¹⁵ and Sivia Lapidus ²⁶ for the CARRA investigators, ¹Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, ²Stony Brook Children's Hospital, Stony Brook, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, ⁴Alberta Children's Hospital, Calgary, Canada, ⁵Nationwide Children's Hospital, Columbus, ⁶Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ⁷The Hospital for Sick Children and University of Toronto, Toronto, Canada, ⁸Kaiser Permanente San Francisco Medical Center and Autoinflammatory Alliance, San Francisco, ⁹University of Iowa Carver College of Medicine, Iowa City, ¹⁰Johns Hopkins University School of Medicine, Baltimore, ¹¹Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ¹²Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ¹³Dana Children’s Hospital of Tel Aviv Medical Center, Binyamina, Israel, ¹⁴Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ¹⁵Boston Children's Hospital, Boston, ¹⁶UCSF Benioff Children’s Hospital, Oakland, ¹⁷Alpert Medical School, Brown University, Providence, ¹⁸Rutgers Robert Wood Johnson Medical School, Metuchen, ¹⁹The Hospital for Sick Children, University of Toronto, Toronto, Canada, ²⁰Stanford University, Los Altos, ²¹Children's National Medical Center, Washington, ²²Shupyk National Medical Academy of Postgraduate Education, Kiev, ²³University of Florida, Gainesville, ²⁴BC Children's Hospital, Vancouver, British Columbia, Canada, ²⁵Dartmouth-Hitchcock Medical Center, Lebanon, ²⁶The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Maplewood
Background/Purpose: International registries have significantly enhanced the understanding of the genetics, phenotype, prognosis, and treatment of Systemic Autoinflammatory Diseases (SAIDs) that could be further augmented…
Abstract Number: 091 • 2020 Pediatric Rheumatology Symposium
Protracted Febrile Myalgia Findings on Magnetic Resonance Imaging
Neta Hana Aviran¹, Liora Harel ², Gil Amarilyo ³, Yosef Uziel ⁴, Yonatan Butbul Aviel ⁵ and Rotem Tal ⁶, ¹Schneider children's medical center of Israel, Kfar Saba, Israel, ²Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ³Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ⁴Kfar Saba, Israel, ⁵Rambam Medical center, Haifa, Hefa, Israel, ⁶schneider medical center, Ramat Gan, Israel
Background/Purpose: Protracted febrile myalgia syndrome (PFMS) is a rare complication of familial Mediterranean fever (FMF) which consist of prolonged attack of fever, excruciating myalgia (up…
Abstract Number: 1256 • 2019 ACR/ARP Annual Meeting
Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over
Serdal Ugurlu¹, Okan Aydin ² and Huri Ozdogan ², ¹Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, istanbul, Turkey, ²Istanul University-Cerrahpasa, istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is a disease with an onset before 20 years of age in 90% of the patients. However late onset FMF defined…
Abstract Number: 1257 • 2019 ACR/ARP Annual Meeting
Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever
Seza Ozen¹, Erdal Sag ², Eldad Ben-Chetrit ³, Marco Gattorno ⁴, Ahmet Gul ⁵, Philip Hashkes ⁶, Isabelle Kone-Paut ⁷, Helen Lachmann ⁸, Elena Tsitsami ⁹, Marinka Twilt ¹⁰, Fabrizio De Benedetti ¹¹ and Jasmin B. Kuemmerle-Deschner ¹², ¹Hacettepe University Hospital, Ankara, Turkey, ²Hacettepe University, Ankara, Turkey, ³Hebrew University, Jerusalem, Israel, ⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Istanbul University, Istanbul, Turkey, ⁶Shaare-Zedek Medical Center, Jerusalem, Israel, ⁷Rhumatologie pédiatrique et CEREMAIA,, Université Paris-Sud Saclay, Paris, France, ⁸The Royal Free Hospital & University College London, London, United Kingdom, ⁹National and Kapodistrian University of Athens, Athens, Greece, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Bambino Gesù Children’s Hospital, Rome, Italy, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease and colchicine is the drug of choice for its treatment. However, about 5-10%…
Abstract Number: 1268 • 2019 ACR/ARP Annual Meeting
Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?
Hakan Emmungil¹, Ufuk İlgen ¹, Sezin Turan ¹, Samet Yaman ² and Orhan Küçükşahin ³, ¹Trakya University, Edirne, Turkey, ²Yıldırım Beyazıt University, Ankara, Turkey, ³Liv Hospital, Ankara, Turkey
Background/Purpose: Colchicine is the mainstay of treatment for prevention of attacks and associated amyloidosis in Familial Mediterranean Fever (FMF). Two approved colchicine preparations are currently…
Abstract Number: 1320 • 2018 ACR/ARHP Annual Meeting
Activity Tracker Bracelets Captures Familial Mediterranean Fever Attacks and Their Impact on Daily Physical Activities
Hakan Babaoglu, Ozkan Varan, Nuh Atas, Hasan Satis, Reyhan Salman, Mehmet Akif Ozturk, Berna Goker, Seminur Haznedaroglu and Abdurrahman Tufan, Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey
Activity Tracker bracelets captures Familial Mediterranean Fever attacks and their impact on daily physical activities Background/Purpose: Familial Mediterranean fever (FMF) is a recessively inherited systemic…
Abstract Number: 1322 • 2018 ACR/ARHP Annual Meeting
Comparison of Serum Hepcidin and Calprotectin Levels in Patients with Familial Mediterranean Fever (FMF) and Healthy Subjects
Gökmen ASAN¹, Mehmet Emin DERİN², Halef Okan DOĞAN³, Meliha BAYRAM⁴, Mehtap ŞAHİN³ and Ali Şahin⁵, ¹İnternal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ²Rheumatology-internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ³Biochemistry, Cumhuriyet University Medical Faculty, sivas, Turkey, ⁴internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ⁵Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease which has self-limiting inflammatory attacks placing in polyserositis. Hepcidin is a protein in peptide structure and…
Abstract Number: 1323 • 2018 ACR/ARHP Annual Meeting
Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF)
Meliha BAYRAM¹, Mehmet Emin DERİN², Halef Okan DOĞAN³, Gökmen ASAN⁴, Mehtap ŞAHİN³ and Ali Şahin⁵, ¹internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ²Rheumatology-internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ³Biochemistry, Cumhuriyet University Medical Faculty, sivas, Turkey, ⁴İnternal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, ⁵Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey
Background/Purpose: Familial Mediterranean Fever(FMF) is an autoinflammatory disease characterized by recurrent fever attacks, sterile peritonitis, pleural inflammation, arthritis and / or erysipelas like rash. Prolidase…
Abstract Number: 2148 • 2018 ACR/ARHP Annual Meeting
Prevalence and Incidence of FMF in Germany – Results of the First Retrospective Analysis of Representative Claims Data
Ivan Foeldvari¹, Katharina Boehm², Thomas Kramps² and Lukas Mayerhoff³, ¹Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ²Novartis Pharma GmbH, Nuremberg, Germany, ³Elsevier GmbH, Munich, Germany
Background/Purpose: Familial Mediterranean fever (FMF) is a rare hereditary autoinflammatory disease that predominantly affects, but is not limited to, persons of Middle Eastern ancestry. In…
Abstract Number: 942 • 2017 ACR/ARHP Annual Meeting
Role of the Pyrin Inflammasome in Resistance to Yersinia Pestis: A Possible Selective Advantage for Carriers of MEFV Mutations
Yong Hwan Park¹, Wonyong Lee¹, Lawton Chung², James Bliska², Daniel L. Kastner¹ and Jae Jin Chae³, ¹Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²Department of Molecular Genetics and Microbiology, School of Medicine, Stony Brook University, Stony Brook, NY, ³Inflammatory disease section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Mutations in MEFV, encoding pyrin, cause the prototypic autoinflammatory disease, familial Mediterranean fever (FMF). The carrier frequency of FMF-associated MEFV mutations is extraordinarily high…
Abstract Number: 361 • 2017 ACR/ARHP Annual Meeting
Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
Jasmin B. Kuemmerle-Deschner¹, Pierre Quartier², Shai Padeh³, Isabelle Koné-Paut⁴, Veronique Hentgen⁵, Katherine A. Marzan⁶, Fatma Dedeoglu⁷, Helen J. Lachmann⁸, Tilmann Kallinich⁹, Norbert Blank¹⁰, Seza Ozen¹¹, Yelda Bilginer¹², Jonathan S. Hausmann^7,13, Arturo Diaz¹³, Ravi Degun¹⁴, Nina Marinsek¹⁴, Jill Gregson¹⁵, Kathleen G. Lomax¹⁶ and Avi Livneh¹⁷, ¹Pediatrics, University Hospital Tübingen, Tübingen, Germany, ²Necker-Enfants Malades Hospital, Paris, France, ³Sheba Medical Center, Tel-Hashomer, Israel, ⁴Bicêtre Hospital, APHP, Univeristy Paris Sud, Paris, France, ⁵Versailles Hospital, CEREMAI, Le Chesnay, France, ⁶Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁷Boston Children's Hospital, Boston, MA, ⁸UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁹Charité, Humbolt University Medicine Berlin, Berlin, Germany, ¹⁰UniversitätsKlinikum Heidelberg, Heidelberg, Germany, ¹¹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹²Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹³Beth Israel Deaconess Medical Center, Boston, MA, ¹⁴Life Sciences, Navigant Consulting, London, United Kingdom, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Sheba Medical Center, Ramat-Gan, Israel
Background/Purpose: Periodic fever syndromes (PFS) are a group of autoinflammatory disorders characterized by recurrent bouts of fever and severe localized inflammation which, if not treated,…
Abstract Number: 3123 • 2016 ACR/ARHP Annual Meeting
Rare Mediterranean Fever (MEFV) Gene Polymorphisms Are Associated with Ankylosing Spondylitis in Turkish and Iranian Population
Zhixiu Li¹, Servet Akar², Handan Yarkan³, Pinar Cetin³, Gerçek Can³, Gökce Kenar³, Omer Nuri Pamuk⁴, Yavuz Pehlivan⁵, Katie Cremin⁶, Erika De Guzman¹, Jessica Harris¹, Ahmad Reza Jamshidi⁷, Mahdi Vojdanian⁷, Nooshin Ahmadzadeh⁷, Mahdi Mahmoudi⁷, Matthew A. Brown¹ and Nurullah Akkoc³, ¹Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ²Department of Rheumatology, İzmir Katip Çelebi University, School of Medicine, İzmir, Turkey, İzmir, Turkey, ³Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, İzmir, Turkey, İzmir, Turkey, ⁴Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey, ⁵Department of Rheumatology, Uludag University Medical Faculty, Bursa, Turkey, Bursa, Turkey, ⁶The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁷Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran, Tehran, Iran (Islamic Republic of)
Background/Purpose: Ankylosing spondylitis (AS) is a highly heritable inflammatory arthritis common in both Turkish and Iranian populations. Familial Mediterranean Fever (FMF) is an autosomal recessive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].